Study to Assess the Safety and Tolerability of Multiple Ascending Doses of REGN1500
Phase of Trial: Phase I
Latest Information Update: 05 Oct 2015
At a glance
- Drugs Evinacumab (Primary)
- Indications Metabolic disorders
- Focus Adverse reactions
- Sponsors Regeneron Pharmaceuticals
- 29 Sep 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
- 16 Mar 2015 Planned End Date changed from 1 Jun 2015 to 1 Sep 2015 as reported by ClinicalTrials.gov record.
- 16 Mar 2015 Planned primary completion date changed from 1 Jun 2015 to 1 Sep 2015 as reported by ClinicalTrials.gov record.